161 related articles for article (PubMed ID: 16565212)
1. Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG).
Trudeau ME; Crump M; Charpentier D; Yelle L; Bordeleau L; Matthews S; Eisenhauer E
Ann Oncol; 2006 Jun; 17(6):952-6. PubMed ID: 16565212
[TBL] [Abstract][Full Text] [Related]
2. Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study.
Siena S; Crinò L; Danova M; Del Prete S; Cascinu S; Salvagni S; Schiavetto I; Vitali M; Bajetta E
Ann Oncol; 2010 Mar; 21(3):655-661. PubMed ID: 19767314
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of temozolomide using an extended continuous oral schedule.
Brock CS; Newlands ES; Wedge SR; Bower M; Evans H; Colquhoun I; Roddie M; Glaser M; Brampton MH; Rustin GJ
Cancer Res; 1998 Oct; 58(19):4363-7. PubMed ID: 9766665
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases.
Christodoulou C; Bafaloukos D; Kosmidis P; Samantas E; Bamias A; Papakostas P; Karabelis A; Bacoyiannis C; Skarlos DV;
Ann Oncol; 2001 Feb; 12(2):249-54. PubMed ID: 11300333
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma.
Talbot SM; Keohan ML; Hesdorffer M; Orrico R; Bagiella E; Troxel AB; Taub RN
Cancer; 2003 Nov; 98(9):1942-6. PubMed ID: 14584078
[TBL] [Abstract][Full Text] [Related]
6. [Temozolomide as therapeutic option for patients with metastatic melanoma and poor prognosis].
Frick S; Lischner S; Rosien F; Haacke TC; Schäfer F; Christophers E; Hauschild A
Hautarzt; 2002 Oct; 53(10):659-65. PubMed ID: 12297947
[TBL] [Abstract][Full Text] [Related]
7. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study.
Agarwala SS; Kirkwood JM; Gore M; Dreno B; Thatcher N; Czarnetski B; Atkins M; Buzaid A; Skarlos D; Rankin EM
J Clin Oncol; 2004 Jun; 22(11):2101-7. PubMed ID: 15169796
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of temozolomide for patients with recurrent or progressive brain metastases.
Abrey LE; Olson JD; Raizer JJ; Mack M; Rodavitch A; Boutros DY; Malkin MG
J Neurooncol; 2001 Jul; 53(3):259-65. PubMed ID: 11718258
[TBL] [Abstract][Full Text] [Related]
9. Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases.
Addeo R; De Rosa C; Faiola V; Leo L; Cennamo G; Montella L; Guarrasi R; Vincenzi B; Caraglia M; Del Prete S
Cancer; 2008 Nov; 113(9):2524-31. PubMed ID: 18798231
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma.
Rivera E; Meyers C; Groves M; Valero V; Francis D; Arun B; Broglio K; Yin G; Hortobagyi GN; Buchholz T
Cancer; 2006 Sep; 107(6):1348-54. PubMed ID: 16909414
[TBL] [Abstract][Full Text] [Related]
11. Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study.
Schadendorf D; Hauschild A; Ugurel S; Thoelke A; Egberts F; Kreissig M; Linse R; Trefzer U; Vogt T; Tilgen W; Mohr P; Garbe C
Ann Oncol; 2006 Oct; 17(10):1592-7. PubMed ID: 17005632
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas.
Garcia del Muro X; Lopez-Pousa A; Martin J; Buesa JM; Martinez-Trufero J; Casado A; Poveda A; Cruz J; Bover I; Maurel J;
Cancer; 2005 Oct; 104(8):1706-12. PubMed ID: 16134177
[TBL] [Abstract][Full Text] [Related]
13. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Nicholson HS; Kretschmar CS; Krailo M; Bernstein M; Kadota R; Fort D; Friedman H; Harris MB; Tedeschi-Blok N; Mazewski C; Sato J; Reaman GH
Cancer; 2007 Oct; 110(7):1542-50. PubMed ID: 17705175
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases.
Bael TE; Peterson BL; Gollob JA
Melanoma Res; 2008 Apr; 18(2):147-51. PubMed ID: 18337652
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of extended low-dose temozolomide in recurrent malignant gliomas.
Khan RB; Raizer JJ; Malkin MG; Bazylewicz KA; Abrey LE
Neuro Oncol; 2002 Jan; 4(1):39-43. PubMed ID: 11772431
[TBL] [Abstract][Full Text] [Related]
16. A phase II evaluation of Temozolomide in patients with recurrent epithelial ovarian cancer.
Judson PL; Blair Harkness C; Boente MP; Downs LS; Argenta PA; Carson LF
Gynecol Oncol; 2004 Jun; 93(3):667-70. PubMed ID: 15196862
[TBL] [Abstract][Full Text] [Related]
17. Chemosensitized radiosurgery for recurrent brain metastases.
Roberge D; Souhami L; Fortin MA; Pouliot JF
J Neurooncol; 2012 Nov; 110(2):265-70. PubMed ID: 22910852
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of temozolomide for leptomeningeal metastases in patients with solid tumors.
Segura PP; Gil M; Balañá C; Chacón I; Langa JM; Martín M; Bruna J
J Neurooncol; 2012 Aug; 109(1):137-42. PubMed ID: 22610937
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group.
Estlin EJ; Lashford L; Ablett S; Price L; Gowing R; Gholkar A; Kohler J; Lewis IJ; Morland B; Pinkerton CR; Stevens MC; Mott M; Stevens R; Newell DR; Walker D; Dicks-Mireaux C; McDowell H; Reidenberg P; Statkevich P; Marco A; Batra V; Dugan M; Pearson AD
Br J Cancer; 1998 Sep; 78(5):652-61. PubMed ID: 9744506
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of two-weekly temozolomide in patients with high-grade gliomas.
Wong S; Rosenthal MA; Dowling A; Jennens R; Woods AM; Ashley D; Cher L
J Clin Neurosci; 2006 Jan; 13(1):18-22. PubMed ID: 16356721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
